ALTEOGEN Inc.
Research ALTEOGEN Inc. (196170) on Bullrun: market cap KRW 19.32T, dividend yield 0.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker196170
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 19.32T
- Dividend yield0.1%
- Financial periodQ1 2026
- RevenueKRW 71.60B
- Net incomeKRW 71.70B
- Free cash flowKRW 6.78B
- Gross margin85.9%
Valuation Snapshot
latest market cap is KRW 19.32T; dividend yield is 0.1%.
About ALTEOGEN Inc.
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial;
Frequently asked questions
What is ALTEOGEN Inc.'s market cap?
ALTEOGEN Inc.'s market capitalization is KRW 19.32T.
Does ALTEOGEN Inc. pay a dividend?
ALTEOGEN Inc. has a dividend yield of 0.1%.
What does ALTEOGEN Inc. do?
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial;